TUESDAY, July 20, 2021 (HealthDay News) — A preference-based health utility score (PROPr), calculated using Patient-Reported Outcomes Measurement Information System (PROMIS) domain scores, appears to be valid for assessing health-related quality of life among patients treated with kidney replacement therapy, according to a study published online July 16 in the Clinical Journal of the American Society of Nephrology.
Jing Zhang, M.P.H., from the University Health Network and University of Toronto, and colleagues assessed the construct validity of PROPr, generated from seven domains, among patients treated with kidney replacement therapy. Correlations between PROPr and Short form 6-domain (SF-6D) or EuroQoL 5-domain 5-level (EQ-5D-5L) scores were used to assess construct validity. Data were included for 524 participants with a mean age of 57 years.
The researchers found that the median scores for PROPr, SF-6D, and EQ-5D-5L were 0.39, 0.69, and 0.85, respectively. There were large correlations observed between PROPr and SF-6D and between PROPr and EQ-5D-5L (0.79 and 0.71, respectively). Health condition impact was demonstrated in the expected direction for both PROPr and the other utility indices. For PROPr, the estimates were −0.17, −0.05, and −0.28, respectively, for dialysis versus kidney transplant, kidney transplant with estimated glomerular filtration rate <45 versus ≥45 mL/min/1.73 m2, and moderate/severe depressive symptoms compared with no or mild depressive symptoms.
“Our results open the doors for the use of PROPr and PROMIS tools in nephrology research and in the care of patients with kidney failure,” a coauthor said in a statement.
Copyright © 2021 HealthDay. All rights reserved.